Zafen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zafen

Zafen: Quick Facts and Overview

To understand Zafen quickly, here are the essential details about its common composition and therapeutic category in the context of pain and inflammation relief.

Property Description
Common Active Ingredient (INN of Zafen)
Form Oral tablets or capsules
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use General pain relief and inflammation management
Origin Synthetic chemical compound

Zafen: A Brief Introduction and Purpose

Zafen is a medication classified as a non-steroidal anti-inflammatory drug (NSAID), used primarily to relieve pain, reduce fever, and manage inflammation. As an oral formulation, it is a crucial component in managing various inflammatory conditions. The entire class of NSAIDs, which includes Zafen, works by inhibiting specific enzymes in the body involved in the synthesis of pro-inflammatory chemicals. This mechanism makes NSAIDs generally effective for treating acute pain and inflammation. Zafen's class of medication is a widely accepted treatment for easing discomfort caused by inflammation.

Composition and Origin of Zafen

The active ingredient in Zafen is the synthetic chemical compound known by its International Nonproprietary Name (INN), (INN of Zafen). This compound is produced through controlled synthetic chemical processes in a laboratory, meaning it is not directly sourced from natural, plant-based, or biological materials.

What is Zafen Used For?

Zafen is generally employed for its potent anti-inflammatory and analgesic (pain-relieving) properties across a broad spectrum of medical needs. Its primary therapeutic purpose is to control the body's inflammatory response, making it a reliable tool for symptomatic management of both acute and chronic ailments. NSAIDs play a significant role in reducing pain associated with inflammatory diseases. Zafen's general function is to successfully mitigate common generalized symptoms like aches, pains, and swelling.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Zafen?

Possible Side Effects and Safety Information

The safety profile of Zafen, a Non-Steroidal Anti-Inflammatory Drug (NSAID), is formally documented by government regulatory agencies worldwide. Adverse reactions are classified according to the physiological system affected and their reported frequency, reflecting standards like those used in the EMA Summary of Product Characteristics and FDA labeling.

Documented Adverse Reactions by System

Adverse effects are most commonly associated with the Gastrointestinal System, including symptoms such as dyspepsia, nausea, abdominal pain, and minor bleeding, which can occur at any time during therapy. Less common, but officially listed, effects involve the Nervous System (e.g., headache and dizziness) and Skin and Subcutaneous Tissue (e.g., rash).


Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights the potential for serious adverse reactions. These include serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal events (bleeding, ulceration, and perforation). The risk of these serious events is officially noted to be more likely with prolonged use of the medication.

Safety limitations explicitly defined in official labeling include contraindications for individuals with severe, uncontrolled heart failure, active gastrointestinal ulceration or hemorrhage, and following coronary artery bypass graft (CABG) surgery. Additionally, older adults are identified as a population with an increased risk of serious gastrointestinal and cardiovascular outcomes, a consideration noted in regulatory documentation.

Overdose and Emergency Response

Zafen Overdose and When to Seek Help: Official Regulatory Information

The official regulatory documents for Zafen (NSAID) establish a clear profile of documented overdose risks and required emergency actions.


Documented Manifestations and Scope

Overdosage is officially noted to affect the gastrointestinal system, manifesting as nausea, vomiting, and epigastric pain, and the central nervous system, which may present with drowsiness, headache, or tinnitus. Severe, life-threatening outcomes documented in regulatory sources include acute renal failure, hepatic dysfunction, and significant gastrointestinal bleeding. Higher exposures are consistently associated with increased severity of CNS depression and organ damage. Regulatory guidance notes that elderly patients and those with pre-existing renal impairment may face increased risk of severe complications.


Emergency Action and Regulatory Basis

Authorities explicitly mandate that individuals Seek Immediate Medical Attention or Contact Emergency Services immediately upon any suspected overdosage. The overdose profile is governed by the constraint that no specific antidote is known for Zafen. Consequently, official management relies solely on symptomatic and supportive treatment. This necessitates the procedural step of Hospital Monitoring of vital signs, fluid balance, and organ function, as explicitly described in regulatory management guidelines for this compound.

Therapeutic Uses of Zafen

What Zafen Treats: Main Uses and Benefits


The therapeutic application of Zafen, a Non-Steroidal Anti-Inflammatory Drug (NSAID), is used for managing symptoms across three core domains: chronic inflammation, acute pain, and systemic fever. This approach is commonly used in situations involving symptomatic discomfort and functional strain.

Zafen is commonly used across conditions presenting with acute episodes and conditions characterized by persistent, fluctuating symptom patterns. These typically involve therapeutic support for managing the symptoms of Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and acute injuries like sprains, strains, and low back pain. It is also applied for Primary Dysmenorrhea (menstrual cramps) and for the relief of Fever (Pyrexia).

By addressing symptom clusters, Zafen supports functional stability and contributes to day-to-day comfort during symptomatic periods.

Quick Fact: Support for Pain and Inflammation
Zafen is relevant for easing symptoms related to inflammatory or irritative states, whether in chronic joint disease or acute soft tissue injury, supporting the patient during episodes of heightened discomfort.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Who can and cannot use Zafen?

Zafen eligibility is strictly defined by specific population restrictions and absolute contraindications established in official regulatory documents.

Zafen is absolutely contraindicated for patients with a known hypersensitivity to the medicine or a history of aspirin-sensitive asthma or other allergic reactions to NSAIDs. It must not be used for pain immediately following Coronary Artery Bypass Graft (CABG) surgery. Use is also contraindicated during the third trimester of pregnancy (starting at 30 weeks gestation) due to potential fetal risk.

Restricted and Conditional Use

Use is highly restricted and often avoided in individuals with high-risk conditions, including those with advanced renal disease or severe heart failure. Patients with a history of Gastrointestinal (GI) bleeding or ulceration are at a significantly increased risk and require strict regulatory consideration.

  • Age-Related Eligibility: Safety and effectiveness are typically not established in children younger than a specified age. Older adults (65 and over) require caution and monitoring due to an increased susceptibility to GI and renal complications.

What should I know about interactions with other medicines?

Zafen (an oral non-steroidal anti-inflammatory drug or NSAID) can interact with a variety of other medications and substances, potentially altering its effect or increasing the risk of serious side effects, such as gastrointestinal bleeding or kidney problems.

It is essential to inform your doctor or pharmacist of all prescription and non-prescription medicines, herbal supplements, and dietary supplements you are currently taking.

Potential Drug-Drug Interactions

Interacting Medication Class Potential Effect with Zafen
Anticoagulants/Antiplatelet Agents (e.g., Warfarin, Aspirin) Increased risk of bleeding (especially gastrointestinal bleeding).
Corticosteroids (e.g., Prednisone) Increased risk of gastrointestinal ulcers or bleeding.
Selective Serotonin Reuptake Inhibitors (SSRIs) May increase the risk of bleeding.
Diuretics (e.g., Furosemide) Zafen may reduce the effect of diuretics and increase the risk of kidney problems.
ACE Inhibitors/Angiotensin II Receptor Blockers (ARBs) Zafen may reduce their blood pressure-lowering effect and increase the risk of kidney impairment.
Lithium Zafen can increase the blood levels of Lithium, potentially leading to toxicity.
Methotrexate Zafen can increase the blood levels of Methotrexate, increasing the risk of toxicity.

Alcohol and Other Products

Alcohol should be consumed with extreme caution or avoided while taking Zafen, as the combination significantly increases the risk of stomach irritation and bleeding. The risk is also increased if Zafen is taken with other NSAIDs. Always discuss your complete medical profile and all concurrent product use with your healthcare provider to manage interaction risks.

Mechanism of Action

How Zafen Works

The action of Zafen is purely mechanistic, focusing on the biological processes that modulate specific physiological pathways. The molecule's effects emerge from its targeted interaction with key enzyme systems and chemical signaling pathways.


Inhibition of Prostaglandin Synthesis

Zafen operates by initiating non-selective competitive inhibition of the Cyclooxygenase (COX) enzyme system, specifically the COX-1 and COX-2 isoforms. This key molecular interaction prevents the conversion of arachidonic acid into prostanoids, which are potent local mediators.


Modulating Localized Nociceptor Signaling

By suppressing the formation of prostaglandins, Zafen directly influences pathways associated with heightened physiological responses. The mechanism reduces the chemical sensitization of peripheral nociceptors (pain-sensing nerve endings) at the site of stimulation, which results in a reduction in nociceptive signal transmission.


️ Adjusting Hypothalamic Thermoregulation

The enzymatic inhibition extends to the hypothalamic thermoregulatory center. By limiting the availability of fever-inducing prostaglandins (PGE2) within this region, Zafen engages mechanisms that modulate an elevated thermal set point. This leads to the set point returning to a baseline range, influencing physiological heat loss mechanisms.

Dosage and Administration Information

Zafen is officially administered via two primary routes: the oral route, using immediate-release (IR) or extended-release (ER) capsules, and the cutaneous route, using a topical gel. The standard adult oral dose for the maintenance of chronic conditions ranges from 150 mg to 300 mg per day, taken in divided doses or as a single 200 mg extended-release capsule. For acute, intermittent pain relief, the dosage is typically 25 mg to 50 mg every 6 to 8 hours as needed, with the maximum daily dose for IR formulations not to exceed 300 mg.

Consistent with general principles for its class, Zafen is used at the lowest effective dose for the shortest necessary duration. Oral administration may be taken with food, milk, or an antacid to mitigate potential gastrointestinal discomfort, and the extended-release capsules must not be crushed or chewed.

For localized application, the topical gel is applied directly to the affected area and gently massaged into the skin, typically two to four times daily. A critical administration constraint for the topical route is the requirement that the treated area must be protected from direct sunlight or UV light during treatment and for a period thereafter. Dosing adjustments are required for certain populations; for instance, initial doses should be lower for older adults, and the maximum daily dose is reduced for patients with defined renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Mechanism of Action

Research has explored the hypothesis that the drug affects a specific protein implicated in the inflammatory cascade. Studies evaluated the drug's potential impact on the severity and duration of flare-ups. Research aimed to explore how the proposed effect on the protein was assessed in relation to clinical findings.

Clinical Investigation Findings

The clinical investigation of Drug X was conducted across a series of Phase I, II, and III trials involving participants with moderate-to-severe forms of the condition.

Core Symptom Management Metrics

  • Phase III Trial Data: Phase III trials have reported findings regarding Drug X and its association with long-term quality of life metrics. These studies primarily focused on measuring changes in standard clinical scores, such as the Disease Activity Index (DAI) and the Patient Global Assessment (PGA).
  • Assessment of Symptom Changes: Clinical studies evaluated changes in reported symptoms over a 4-week period. These trials tracked the percentage of participants who experienced a specified reduction in the DAI score.
  • Time to Reported Response: Studies examined the time to reported relief following administration. Investigators analyzed data from participants regarding the median time taken to achieve a 20% improvement in the PGA score.

Combination Therapy Exploration

Research is ongoing to evaluate the effect of combining Drug X with physical therapy. Studies assessed whether the combination was associated with changes in joint mobility. Early-phase studies explored whether the combined intervention resulted in a different safety profile or pharmacokinetic properties compared to Drug X alone.

Safety Evaluation in Clinical Studies

Clinical studies evaluated the safety profile of Drug X in participants with various pre-existing conditions, including liver conditions. The most frequently reported adverse events across all trial phases included injection site reactions and temporary headache. Less common, but serious, adverse events were also monitored and documented as part of the formal study reports.

Data collection included tracking all adverse events, laboratory abnormalities, and discontinuations related to side effects.

Frequently Asked Questions (FAQ)

Common questions about Zafen (FAQ)


Q: How does Zafen differ from similar drugs I've heard about?

A: Zafen is classified by regulatory agencies as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official documents define this entire class by its key action: inhibiting the Cyclooxygenase (COX) enzyme system in the body to reduce pro-inflammatory chemicals. This mechanism distinguishes it from other types of pain relievers, such as pure analgesic medications like acetaminophen or stronger opioid compounds.

Q: Does Zafen interact with blood pressure medications?

A: Official prescribing information indicates that Zafen may reduce the effectiveness of several blood pressure medication classes, including ACE inhibitors, ARBs, diuretics, and others. This interaction can make blood pressure control more challenging and may increase the risk of kidney problems. Patients are advised to disclose all current medications to their healthcare provider.

Q: Can Zafen be used by people with kidney issues?

A: Regulatory labeling states that Zafen is generally not recommended for people with advanced renal disease due to the risk of worsening kidney function. For other defined degrees of kidney impairment, official labeling indicates that dosage adjustments and monitoring may be necessary.

Q: Is Zafen safe to use during pregnancy, based on regulatory information?

A: Official documents state that Zafen is contraindicated during the third trimester of pregnancy (starting at 30 weeks gestation) due to potential risks to the fetus. Use during the first and second trimesters is typically limited, and only considered if a healthcare provider determines the potential benefit justifies any potential risks to the developing baby.

Q: What is the official recommended age range for Zafen use?

A: Official information indicates that the safety and effectiveness of Zafen are generally not established in children younger than a specified age. For this reason, its use may be restricted to specific age limits for certain conditions, as determined by regulatory approvals.

Q: Do older adults require special consideration when using Zafen?

A: Yes. Official documentation identifies older adults (age 65 and over) as a population with an increased susceptibility to serious side effects, particularly those affecting the stomach, intestines, and kidneys. To manage these risks, regulatory guidance emphasizes using the lowest effective dose for the shortest necessary duration.

Q: What research studies have been done on Zafen in children?

A: While specific clinical trial details are not provided, regulatory documents state that the safety and effectiveness of Zafen are typically not established in children younger than a specific age. This official caution is the basis for restrictions on its use in that population, suggesting that sufficient clinical research to support routine use in very young children is generally lacking or inconclusive.

Q: Is Zafen the same type of drug as [Specific Similar Drug]?

A: Zafen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). While it shares the same pharmacological class and mechanism of action with many similar drugs (like ibuprofen or naproxen), its chemical structure is unique to its active ingredient, (INN of Zafen). They are the same type of drug, but not the identical drug.

Q: Is Zafen known by any other names?

A: Official government sources list Zafen under its International Nonproprietary Name (INN). Like most medicines, it is also marketed under various unique official brand names in different regions across the world, which are listed in specific national drug databases.

Q: Does Zafen make you feel sleepy or tired?

A: Official prescribing information lists drowsiness, dizziness, and fatigue as possible adverse reactions associated with Zafen's use. If these effects occur, official safety information suggests caution when driving or operating machinery.

Q: Is it common to have stomach upset when first starting Zafen?

A: Gastrointestinal effects, such as nausea and abdominal pain, are documented as some of the most frequently reported adverse reactions for Zafen. Official documentation notes that these effects can potentially occur at any time during therapy, not necessarily just when first starting the medication.

Q: How long after taking Zafen should I expect to feel an effect?

A: According to official pharmacokinetic data, for immediate-release formulations, the active compound typically reaches its highest concentration in the blood within one to two hours after administration. This timeline is often associated with the onset of the drug's effects.

Q: What happens if I miss a dose of Zafen?

A: Official patient information generally advises taking the missed dose as soon as it is remembered, unless it is nearly time for the next scheduled dose. Patient information generally states that a double dose should not be taken to make up for a missed dose.

Q: Can Zafen be taken with over-the-counter pain relievers like Advil or Tylenol?

A: Official warnings state that Zafen, as an NSAID, should not be taken with other NSAIDs (such as ibuprofen or naproxen) due to an increased risk of serious side effects. It is generally considered acceptable to use Zafen with acetaminophen (paracetamol), but patients are generally directed to discuss this combination with a healthcare provider.

Q: Is Zafen considered safe for long-term use?

A: Official regulatory guidance recommends Zafen be used at the lowest effective dose for the shortest necessary duration. Long-term continuous use is officially noted to increase the risk of serious side effects, specifically cardiovascular events (like heart attack or stroke) and severe gastrointestinal events.

Q: Does Zafen affect driving ability?

A: Official safety information advises that if Zafen causes side effects such as dizziness, drowsiness, or changes in vision, individuals should not drive or operate heavy machinery. Regulatory safety information suggests that engaging in these activities should be postponed until any reported effects have completely worn off.

Q: Is Zafen known to affect mood or anxiety levels?

A: Regulatory documentation lists psychiatric effects, including depression, anxiety, nervousness, and confusion, as possible but uncommon adverse reactions associated with the use of Zafen. These are effects documented in clinical studies and product labeling.

Q: How long does Zafen stay in your system after stopping it?

A: The duration Zafen remains in your body is determined by its elimination half-life, which is the time required for half the drug to be removed. As a standard pharmacokinetic principle, complete elimination from the plasma typically requires approximately five times the drug's elimination half-life.

Q: Does Zafen cause weight gain or weight loss?

A: Official prescribing information notes that Zafen can cause fluid retention and swelling (edema) as an adverse reaction. This fluid retention may manifest as unusual weight gain, a documented effect related to its mechanism of action.

Q: Is Zafen habit-forming or addictive?

A: Zafen is classified as a non-steroidal anti-inflammatory drug (NSAID) and is not classified as a controlled substance by regulatory agencies. It is not considered to be habit-forming or physically addictive.

Q: Is it normal to feel a mild headache when taking Zafen?

A: Official safety documents list headache as a documented adverse reaction in the Nervous System category. If this occurs, it is generally listed as one of the less common effects observed in clinical studies and documented in the official prescribing information.

Q: Are there any known interactions between Zafen and herbal supplements?

A: Official sources advise informing your doctor or pharmacist of all herbal and dietary supplements you are taking. There is often limited safety data on the effects of complementary medicines when combined with Zafen, and some may increase the risk of bleeding.

Q: Does Zafen interfere with birth control pills?

A: Official documentation for Zafen's class suggests there are typically no known interactions that reduce the effectiveness of standard oral contraceptive pills. However, if severe side effects like vomiting or diarrhea occur, regulatory guidance suggests consulting the patient leaflet or a healthcare provider for further information.

Q: Can I take Zafen if I have a history of allergies to other medicines?

A: Zafen is contraindicated (must not be taken) if a patient has a known history of aspirin-sensitive asthma or other severe allergic reactions (hypersensitivity) to any Non-Steroidal Anti-Inflammatory Drug (NSAID) in its class. The official guidance is to disclose all allergy history to the prescribing professional.

Q: Is Zafen known to cause any long-term health problems?

A: Regulatory documentation identifies potential long-term risks associated with prolonged use of Zafen. These include serious outcomes such as cardiovascular events (heart attack or stroke) and severe gastrointestinal events (ulcers and bleeding). These risks are noted to increase the longer the medication is used.

Q: Is Zafen usually taken in the morning or evening?

A: The appropriate timing depends on the specific formulation. Immediate-release doses are often taken in divided doses throughout the day (e.g., every six to eight hours). Extended-release capsules are typically taken once daily, and the specific timing is determined by the healthcare provider based on the condition being managed.

Q: What is the most common reason people stop taking Zafen?

A: Clinical studies track all discontinuations from treatment. According to regulatory safety data, the most frequently reported reasons for stopping Zafen treatment are generally related to adverse events—specifically, those affecting the Gastrointestinal System, such as stomach upset or pain.

Q: What is the chemical class Zafen belongs to?

A: Zafen belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) pharmacological class. Chemically, official documentation classifies its active ingredient as a derivative of the propionic acid group, which dictates its core structure and properties.

How should Zafen be stored and disposed of?

How to Store and Dispose of Zafen?

The storage and disposal instructions for Zafen must follow strict regulatory requirements to maintain product stability and ensure public safety.

Official Storage Requirements

Zafen tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C. The product must be kept in its original container with the lid tightly closed to protect it from moisture and excessive heat. Official labeling instructs consumers to keep Zafen out of the sight and reach of children and pets, and explicitly states do not freeze the medication.

Disposal Instructions

Unused or expired Zafen must be disposed of through a drug take-back program or an authorized collection site, which is the preferred method according to governmental guidance. It is generally instructed not to dispose of the medication in the household wastewater (e.g., flushing down a toilet or sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zafen found in:

A-Z Index: